Drug Pricing and Biolab Safety Concerns

This chapter explores the stark differences in drug pricing between the United States and Europe, emphasizing the higher costs borne by American consumers. It reveals a troubling incident at a National Institute of Health biolab that raises critical safety concerns and discusses the implications of recent executive orders regarding gain-of-function research. The conversation underscores the necessity for stringent safety protocols in the context of potential pandemics and the need for public engagement in scientific research decisions.